全文获取类型
收费全文 | 5756篇 |
免费 | 364篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 107篇 |
妇产科学 | 191篇 |
基础医学 | 1052篇 |
口腔科学 | 507篇 |
临床医学 | 466篇 |
内科学 | 1059篇 |
皮肤病学 | 145篇 |
神经病学 | 515篇 |
特种医学 | 155篇 |
外科学 | 730篇 |
综合类 | 38篇 |
一般理论 | 8篇 |
预防医学 | 443篇 |
眼科学 | 110篇 |
药学 | 298篇 |
中国医学 | 22篇 |
肿瘤学 | 245篇 |
出版年
2023年 | 43篇 |
2022年 | 90篇 |
2021年 | 164篇 |
2020年 | 111篇 |
2019年 | 141篇 |
2018年 | 185篇 |
2017年 | 112篇 |
2016年 | 160篇 |
2015年 | 162篇 |
2014年 | 210篇 |
2013年 | 293篇 |
2012年 | 375篇 |
2011年 | 420篇 |
2010年 | 248篇 |
2009年 | 229篇 |
2008年 | 359篇 |
2007年 | 343篇 |
2006年 | 256篇 |
2005年 | 211篇 |
2004年 | 231篇 |
2003年 | 190篇 |
2002年 | 170篇 |
2001年 | 160篇 |
2000年 | 148篇 |
1999年 | 113篇 |
1998年 | 49篇 |
1997年 | 33篇 |
1996年 | 41篇 |
1995年 | 24篇 |
1994年 | 31篇 |
1993年 | 24篇 |
1992年 | 48篇 |
1991年 | 43篇 |
1990年 | 42篇 |
1989年 | 41篇 |
1988年 | 53篇 |
1987年 | 35篇 |
1986年 | 46篇 |
1985年 | 45篇 |
1984年 | 25篇 |
1983年 | 36篇 |
1982年 | 26篇 |
1981年 | 30篇 |
1980年 | 22篇 |
1979年 | 25篇 |
1977年 | 20篇 |
1975年 | 26篇 |
1971年 | 22篇 |
1970年 | 30篇 |
1969年 | 18篇 |
排序方式: 共有6138条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Mariana Spitz Alexandre Aluízio Costa Machado Rodrigo do Carmo Carvalho Fernanda Martins Maia Monica Santoro Haddad Dagoberto Calegaro Milberto Scaff Egberto Reis Barbosa 《Movement disorders》2006,21(9):1520-1522
We report on 3 patients with pseudoathetosis, which are involuntary, slow, writhing movements due to loss of proprioception. 相似文献
6.
A case of testicular cancer in 2 brothers is reported and a review of the literature about testicular malignancies and etiologic factors in closely related family members is given. The familial incidence of testicular tumor is found to be 3% in twins and 0.6-2.1% in less closely related men. Tumors were of the same histology in 70-77% of the twins, whereas in brothers and in other degrees of relationship tumors of different histology mostly occur. Following the diagnosis of the tumor in the first man, the average interval to presentation of the tumor in the relative was 3.7 years in twins, 7.7 years in nontwin brothers and 13.5 years for less closely related men. The need for a thorough checkup of other family members is advised. 相似文献
7.
Milena Soares Santos Guilherme de Sousa Ribeiro Tainara Queiroz Oliveira Renan Cardoso Nery Santos Edilane Gouveia Kátia Salgado Daniele Takahashi Cleuber Fontes Leila Carvalho Campos Mitermayer Galvão Reis Albert Icksang Ko Joice Neves Reis 《International journal of infectious diseases》2009,13(4):456-461
8.
G Gaitanis K Nomikos E Vava EC Alexopoulos ID Bassukas 《Journal of the European Academy of Dermatology and Venereology》2009,23(12):1427-1431
Background/aim Theoretical considerations support the combination of cryosurgery and topical imiquimod to treat basal cell carcinomas (BCC). The aim of the present study was to test the feasibility and efficacy of 'cryosurgery during continued imiquimod application' ('immunocryosurgery') to treat 'high-risk-for-recurrence' BCCs.
Methods Thirteen patients with 21 biopsy-proven tumours (4 of 21 relapses after prior surgery) were included. After 2–5 weeks (median, 3) of daily 5% imiquimod cream application, the tumours were treated by liquid N2 cryosurgery (spray, two cycles, 10–20 s) and imiquimod was continued for additional 2–12 weeks (median, 4). The outcome after at least 18 months of follow-up (18–24 months) is currently reported.
Results Nineteen of 21 tumours responded promptly to immunocryosurgery; two tumours required additional treatment cycles to clear. Thus, the clinical clearance rate was 100%. Only 1 of 21(5%) tumour relapsed after at least 18 months of follow-up (cumulative efficacy: 95%).
Conclusions 'Immunocryosurgery' is a promising non-surgical combination modality to treat 'high-risk-for-recurrence BCCs'. Initial evidence is suggestive of an at least additive effect of the two combined modalities. Further studies comparing immunocryosurgery directly with cryosurgery and imiquimod monotherapies will confirm the reported results. 相似文献
Methods Thirteen patients with 21 biopsy-proven tumours (4 of 21 relapses after prior surgery) were included. After 2–5 weeks (median, 3) of daily 5% imiquimod cream application, the tumours were treated by liquid N
Results Nineteen of 21 tumours responded promptly to immunocryosurgery; two tumours required additional treatment cycles to clear. Thus, the clinical clearance rate was 100%. Only 1 of 21(5%) tumour relapsed after at least 18 months of follow-up (cumulative efficacy: 95%).
Conclusions 'Immunocryosurgery' is a promising non-surgical combination modality to treat 'high-risk-for-recurrence BCCs'. Initial evidence is suggestive of an at least additive effect of the two combined modalities. Further studies comparing immunocryosurgery directly with cryosurgery and imiquimod monotherapies will confirm the reported results. 相似文献
9.
10.
Not infrequently clinical demand dictates that patients receive transfusions of ABO-incompatible platelets when there is a short supply of group-specific platelets. This carries a risk of causing a haemolytic reaction, as illustrated in the clinical case we report. In discussing this potential complication, we suggest a strategy for avoiding it. 相似文献